Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline vs Cytisine for Smoking Cessation in Croatia and Slovenia
NCT04015414Phase 3Completed
- Sponsor
- University of Zagreb
- Start
- Jul 2020
- Primary completion
- Sep 2022
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cytisinicline in Tobacco Use Disorder (TUD), sponsored by University of Zagreb. Primary endpoint: Seven day abstinence from tobacco at 12 weeks. Started Jul 2020; status: completed.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT04015414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015414.